Cargando…
Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218317/ https://www.ncbi.nlm.nih.gov/pubmed/34188921 http://dx.doi.org/10.1002/ccr3.4227 |
| _version_ | 1783710741917859840 |
|---|---|
| author | Dougherty, Sean C. Lynch, Alia C. Hall, Richard D. |
| author_facet | Dougherty, Sean C. Lynch, Alia C. Hall, Richard D. |
| author_sort | Dougherty, Sean C. |
| collection | PubMed |
| description | Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab. |
| format | Online Article Text |
| id | pubmed-8218317 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82183172021-06-28 Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use Dougherty, Sean C. Lynch, Alia C. Hall, Richard D. Clin Case Rep Case Reports Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab. John Wiley and Sons Inc. 2021-06-22 /pmc/articles/PMC8218317/ /pubmed/34188921 http://dx.doi.org/10.1002/ccr3.4227 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Case Reports Dougherty, Sean C. Lynch, Alia C. Hall, Richard D. Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title | Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title_full | Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title_fullStr | Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title_full_unstemmed | Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title_short | Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| title_sort | drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use |
| topic | Case Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218317/ https://www.ncbi.nlm.nih.gov/pubmed/34188921 http://dx.doi.org/10.1002/ccr3.4227 |
| work_keys_str_mv | AT doughertyseanc druginducedimmunemediatedthrombocytopeniasecondarytodurvalumabuse AT lynchaliac druginducedimmunemediatedthrombocytopeniasecondarytodurvalumabuse AT hallrichardd druginducedimmunemediatedthrombocytopeniasecondarytodurvalumabuse |